Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1Peripheral Nervous System Diseases 1Ovarian Neoplasms 1Myeloproliferative Disorders 1Hearing Loss, Sensorineural 1Hearing Loss 1Ear Diseases 1Deafness 1Cognitive Dysfunction 1Chemotherapy-Related Cognitive Impairment 1

Interventions

Peripheral Blood Stem Cell Transplantation 7Busulfan 5ruxolitinib 4Methotrexate 4Cyclosporine 4fludarabine phosphate 3Whole-Body Irradiation 2Mycophenolic Acid 2Flow Cytometry 2Cytogenetic Analysis 2Cytarabine 2Cyclophosphamide 2Antilymphocyte Serum 2venetoclax 1sonidegib 1pomalidomide 1pevonedistat 1pelcitoclax 1lestaurtinib 1givinostat hydrochloride 1givinostat 1ethanolamine oleate 1aldesleukin 1Vitamin E 1Trimethoprim, Sulfamethoxazole Drug Combination 1Trimethoprim 1Transplantation 1Topotecan 1Tacrolimus 1Sulfamethoxazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Polycythemia Vera × Acetylcysteine × Clear all
NCT05123365 2026-03-10

An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms

University of California, Irvine

Phase 1/2 Recruiting
27 enrolled
Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡